The term 'extensively drug-resistant tuberculosis' was coined in 2006 by scientists of the Centers for Disease Control and Prevention (CDC), USA, based on the World Health Organization\'s (WHO) guidelines for management of drug-resistant tuberculosis (TB)[@ref1]. Multidrug-resistant tuberculosis (MDR-TB) is caused by *Mycobacterium tuberculosis* resistant to rifampicin and isoniazid, the two main first line antimicrobials[@ref2]. When MDR *M. tuberculosis* has additional resistance to a fluroquinolone and a second line injectable antibiotic (*i.e*. amikacin, kanamycin or capreomycin), it is designated extensively drug-resistant (XDR)[@ref1][@ref2]. Although clinical treatment failure is indicative of drug resistance, the diagnosis of MDR- and XDR-TB requires the isolation of bacterium and antimicrobial drug susceptibility testing (DST). Therefore, the probability and sensitivity of XDR-TB case-detection in a community are dependent on the coverage and quality of microbiological support services for the management of TB.

Against this backdrop it is very important to know where India stands with the emergence of XDR-TB, in terms of both the burden and the geographic spread. WHO has recognized 58 countries, including India, in which XDR-TB has been detected[@ref3]. The number of XDR-TB formally reported by India\'s Revised National TB Control Programme (RNTCP) to WHO is just one[@ref4]. That particular case was actually detected sometime between 1999 and 2003 in Chennai (Tamil Nadu State)[@ref4]. Currently surveys are under way in Ahmedabad (Gujarat State) and Chennai to measure the frequency of XDR organisms among MDR[@ref5].

Since 2006 there have been many papers published in peer reviewed journals from both public and private sector institutions with their data on XDR-TB. These data have been generated from their mycobacteriology laboratories that have been performing 1^st^ and 2^nd^ line mycobacterial DST for many years. Though accreditation is available for 1^st^ line mycobacterial DST, there is none currently available for 2^nd^ line mycobacterial DST. Therefore, the reported XDR-*M. tuberculosis* isolates in India have not been validated. However, since a large number of such reports have been published in peer-reviewed journals, there is a need to take the situation seriously for its public health implications.

Material & Methods {#sec1-1}
==================

Our strategy was to search PubMed database and use Google search engine to identify papers qualifying the terms 'extensively drug-resistant tuberculosis' or 'XDR tuberculosis' and 'India'. In addition, the data presented at the Round Table Conference on "Challenges of MDR/XDR Tuberculosis in India", organized by the Ranbaxy Science Foundation in New Delhi, on December 12, 2008 were also included[@ref6]. Annual Report of Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, Kerala, was also searched for information on the number of XDR-TB isolates detected as work on molecular biology of MDR and XDR-TB was being done at this Centre[@ref7].

Results {#sec1-2}
=======

A total of 16 publications (14 papers, one meeting abstract and one institutional annual report) were identified ([Table](#T1){ref-type="table"}). Even though the term XDR was coined only in 2006, *M. tuberculosis* conforming to the definition of XDR had been detected in isolates obtained during the years from 1997 to 2007 as shown in [Fig. 1](#F1){ref-type="fig"}. However, the reports were published since 2006.
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![The years during which *M. tuberculosis* isolates were screened for drug sensitivity and MDR and XDR isolates were detected. Information on the exact year(s) in which XDR isolates were identified was not available in the papers from most centres. The numbers indicate the reported XDR *M. tuberculosis* isolates.](IJMR-136-599-g002){#F1}

The geographic distribution of centres that have reported XDR-TB is shown in [Fig. 2](#F2){ref-type="fig"}. These are in the States of Kashmir[@ref8], Delhi[@ref9]--[@ref11], Maharashtra[@ref12][@ref13], Uttar Pradesh[@ref14], West Bengal[@ref15], Gujarat[@ref5], Tamil Nadu[@ref4][@ref16]--[@ref20] and Kerala[@ref7].

![Map of India showing the location of nine cities from where the publications on XDR-TB have emerged. The circles are placed at approximate geographic locations. Except in Delhi with two centres, every other city had only one centre reporting XDR-TB. In Tamil Nadu State there are two centres, Chennai and Vellore.](IJMR-136-599-g003){#F2}

The total number of cases of XDR-TB reported in these 16 publications was 694. There were three reports from Vellore (Tamil Nadu); two reported 45 and 47 cases with focus on clinical aspects[@ref17][@ref18] and one reported 90 isolates from the microbiology laboratory[@ref19]. Since we did not attempt to screen clinical case records to count the number of overlapping cases, we assume that the microbiology laboratory report would have included the clinical cases. Similarly there were two reports from New Delhi TB centre[@ref10][@ref11] with overlapping dates, with the possibility of duplication of 2-4 cases. After discounting all potential duplications a total of 598 cases of XDR-TB have been documented.

This review covered all available sources of information on XDR-TB, but not all reports showed the proportion of XDR organisms among MDR ones[@ref9][@ref18][@ref21]. Thus, in some reports the MDR organisms appeared to be under-represented in comparison with the numbers of reported XDR organisms[@ref18].

Discussion {#sec1-3}
==========

There were limitations in our approach to describe the distribution of XDR-TB. We did not explore the reliability of microbiological methods in various laboratories. The microbiological diagnosis of XDR-TB data included here remain not validated by reference laboratories. National Institute for Tuberculosis Research (NITR) in Chennai is RNTCP\'s Supranational Reference Centre (designated by WHO) and it participates in international external quality assessment for microscopy, culture and DST[@ref22]. In turn, NITR monitors the quality of laboratories in the country on behalf of RNTCP. Two laboratories that reported XDR-TB (New Delhi TB Centre and Christian Medical College at Vellore) are accredited by RNTCP for culture and DST. The Vellore laboratory was the nodal centre for the in-country external quality assessment scheme of the Indian Association of Medical Microbiologists[@ref22]. Hinduja Hospital, Mumbai, is accredited by College of American Pathologists[@ref13].

These reports have originated from 10 tertiary care centres in nine cities, distributed widely in the country. Therefore, the data have no representative value for epidemiological assessment. Many hospitals that diagnose and treat TB may use the recommended sputum smear-examination and/or chest X-ray without culturing the bacterium. Many laboratories with culture facilities for *M. tuberculosis* may not conduct DST even for first line anti-TB drugs to diagnose MDR-TB. When MDR organisms are detected, DST for second line drugs is unlikely to be conducted, being cumbersome and expensive. Thus the true prevalence of XDR-TB remains unknown.

The diagnosis of XDR-TB has enormous implications both for the individual and the community. The choice of anti-TB drugs is limited and the ones available are too expensive and too reactogenic[@ref24]. Treatment outcome is mostly disappointing and case-fatality rate (CFR) is very high - in one report the CFR was 51 per cent within a month of diagnosis[@ref25]. When transmitted to new hosts the organisms will remain XDR, hence progressive primary TB and eventual secondary TB (after the period of latent infection), if occur, will inevitably be due to XDR-TB. Therefore, there is an urgent need to prevent secondary transmission at all costs, barring the curtailment of human rights beyond ethical limits. The tension between individual freedom of movement in society and public health need for its restriction has to be addressed and resolved. These considerations call for urgent national policy and guidelines and innovative design for early diagnosis and case management of XDR-TB.

A national registry of XDR-TB will allow every institution to report cases as soon as they are detected. The bacilli isolated from each case should be collected and verified in a reference laboratory. Therefore, a number of reference laboratories should be established and networked so that the facility is readily accessible. A treatment protocol should be designed and applied under RNTCP supervision on every diagnosed case of XDR-TB. While on treatment, precautions necessary to prevent transmission to members of family and to healthcare workers in contact should be applied. The elements of such precautions need to be urgently defined. There is also an urgent need for effective infection-control measures within clinics and hospitals. Prevention of transmission through reducing the airborne shedding and inhalation inoculation can be achieved by measures to reduce aerosol production and circulation in room air. This must be implemented in every hospital co-ordinated by hospital infection control committees. There has been a report of death of a healthcare worker with XDR-TB, most likely hospital-acquired[@ref26].

In order to inhibit the development of MDR and XDR-TB, better diagnostic algorithm needs to be designed and popularized[@ref27][@ref28]. Based on carefully crafted clinical criteria every case of suspected pulmonary TB should have at least one sputum culture for *M. tuberculosis* in order to substantially improve the diagnostic sensitivity and to allow DST well ahead of clinical treatment failure in case the organism is MDR[@ref27][@ref28]. This will require massive expansion of laboratory capacity throughout the country[@ref29]. Every MDR isolate should be further screened for XDR organisms in reference laboratories. The currently recommended sputum smears for detection of acid fast bacilli (AFB) by Zeihl-Neilsen staining should be supplemented with a more sensitive method using fluorescent microscopy[@ref29].

Treatment of TB by community-based medical practitioners often do not conform the recommended regimen; also many patients interrupt or discontinue treatment. This sets the stage for emergence of MDR- and XDR-TB in India[@ref30]. Many patients with MDR-TB have been documented to have non-standard treatment regimens in the past[@ref18] or had repeatedly defaulted on treatment. Such patients should be identified, counselled and restrained with assistance from family and employers - balancing rights of the individual and safety of society.

Although HIV infection does not by itself increase the probability of developing anti TB drug resistance, the co-morbidity with MDR- or XDR-TB is life threatening to HIV positive people. One study[@ref9] had looked at the prevalence of XDR-TB in HIV infected patients and found that among 54 patients, 12 (22%) had MDR-TB and among them 4 (33.3%) had XDR-TB. All four died within 3 months of diagnosis.

Addressing XDR-TB in India will be a formidable challenge. The strategy of RNTCP has been to minimize the development of MDR-TB by standardized drug regimens and consequently reduce the emergence of XDR bacilli. We suspect that the major cause of emergence of XDR-TB is the widespread practice of non-standard drug regimens in the private sector healthcare settings. Guidelines to fully integrate DOTS and DOTS-Plus (diagnosis and treatment of MDR-TB) have already been brought out by RNTCP[@ref30]. The target is to detect and treat at least 30,000 cases of MDR-TB annually, free of charge, from 2012-2013 onwards[@ref31]. Unless TB treatment in private sector is effectively regulated, the problems of MDR- and XDR-TB will remain largely unrecognized.

In conclusion, reports from just nine cities across India document the presence of XDR-TB in India. There is an urgent need for country-wide surveillance of MDR- and XDR-TB. Massive expansion of quality-assured mycobacteriology laboratories and strict guidelines and protocols are essential for diagnosis and treatment of XDR-TB. Practical and effective infection-containment measures and facilities for intensive counselling of TB patients need to be established. Educating professionals on these elements and school and college students and the public on prevention of TB must also become part of national TB control efforts.

**XDR-TB in India**

This write up on extensively drug resistant tuberculosis in India - a review by Drs Joy Sarojini Michael and T. Jacob John is an interesting attempt to focus on a problem which generates very diverse actions among people, scientific leaders, clinicians and public health personnel. As these reports are based on various tertiary care hospitals, these cannot be extrapolated to estimate the burden of the drug resistance in the community. Secondly, there are very few accredited laboratories for second line of TB drugs in India and as such there can be problems about the interpretation and credibility of the profiles reported by many investigators. Nevertheless, one cannot ignore that the problem needs to be addressed by giving it due importance. However, this should not lead to scare as a very small proportion of MDR isolates has been generally found to be XDR. Many Institutions of Government of India including those of ICMR have been working hard to provide the services and augment the capabilities to accurately diagnose the resistance. Several international agencies are also playing their part. I am sure the infrastructure to accurately diagnose different types of the resistance to second line drugs and management of drug resistant cases will be strengthened over a period of time. Till then the readers should read these reports with caution knowing fully well the limitations but get ready to improve as per the needs to do better.
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